Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Platinum derivatives are commonly used for the treatment of patients with metastatic triple-negative breast cancer (TNBC). However, resistance often develops, leading to treatment failure. This expansion cohort (part C2) of the previously reported phase 1b trial (NCT02157792) is based on the recomme...

Full description

Bibliographic Details
Main Authors: Abramson, V. (Author), Arkenau, H.T (Author), Dean, E. (Author), Diaz-Padilla, I. (Author), Dong, J. (Author), Ferrer-Playan, J. (Author), Fleuranceau-Morel, P. (Author), Goddemeier, T. (Author), Grombacher, T. (Author), Haddad, T.C (Author), Lord, S.R (Author), Middleton, M. (Author), Plummer, R. (Author), Shapiro, G.I (Author), Telli, M.L (Author), Tolaney, S.M (Author), Tutt, A. (Author), Wesolowski, R. (Author)
Format: Article
Language:English
Published: Nature Research 2022
Subjects:
adult
advanced cancer
Article
ATR protein
berzosertib
cancer patient
cisplatin
clinical article
controlled study
female
human
middle aged
overall response rate
phase 1 clinical trial
phase 2 clinical trial
response evaluation criteria in solid tumors
solid malignant neoplasm
triple negative breast cancer
Online Access:View Fulltext in Publisher

Similar Items

Similar Items